{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:04:58Z","timestamp":1790125498648,"version":"4.0.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pimodivir (formerly JNJ-63623872) is a novel, non-nucleoside polymerase complex inhibitor with in vitro activity against influenza A virus, including pandemic 2009 H1N1, H7N9, H5N1 strains as well as neuraminidase- and amantadine-resistant strains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized, double-blind, placebo-controlled, Phase IIa study. Healthy volunteers ( n=104) were inoculated with an influenza A\/Wisconsin\/67\/2005 (H3N2) challenge virus. 72 received pimodivir and 32 placebo. Pimodivir was dosed for 5 days once daily from 24 h after viral inoculation at four dose levels: 100 mg, 400 mg, loading dose 900\/600 mg and loading dose 1,200\/600 mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pimodivir significantly reduced viral shedding (area under the concentration versus time curve [AUC] measured by 50% tissue culture infective dose [TCID\n                      <jats:sub>50<\/jats:sub>\n                      ] or qRT-PCR) versus placebo as measured by cell culture assay in the pooled analysis (Jonckheere-Terpstra dose-response trend test [ P=0.036]). Reductions were observed in viral shedding (AUC, duration and peak measured by grade), influenza-like symptoms (AUC, duration and peak measured by grade) and clinical symptoms (duration and peak measured by grade) for all pimodivir groups versus placebo, significantly so for the 1,200\/600 mg group. In the 1,200\/600 mg group viral shedding (AUC) by qRT-PCR was 0.45 versus 18.4 log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/ml*day for pooled placebo ( P=0.014). Pimodivir was generally safe and well-tolerated with no serious adverse events or adverse events leading to discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pimodivir has potential to not only reduce viral load but to have a clinical impact on patients as a novel treatment for influenza A virus infection. Further trials are therefore warranted to assess pimodivir.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3212","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T09:41:16Z","timestamp":1513330876000},"page":"335-344","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":57,"title":["Pimodivir Treatment in Adult Volunteers Experimentally Inoculated with Live Influenza Virus: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study"],"prefix":"10.1177","volume":"23","author":[{"given":"Jose M","family":"Trevejo","sequence":"first","affiliation":[{"name":"Visterra, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Asmal","sequence":"additional","affiliation":[{"name":"Bluebird Bio, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vingerhoets","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Polo","sequence":"additional","affiliation":[{"name":"Janssen Research & Development LLC, Titusville, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Robertson","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Alkermes Inc., Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara L","family":"Kieffer","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorant","family":"Leopold","sequence":"additional","affiliation":[{"name":"Janssen Research & Development LLC, Titusville, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,5,1]]},"reference":[{"key":"bibr1-IMP3212","unstructured":"WHO. Influenza virus infections in humans (February 2014). (Accessed 22 December 2016.) Available from http:\/\/www.who.int\/influenza\/human_animal_interface\/virology_laboratories_and_vaccines\/influenza_virus_infections_humans_feb14.pdf."},{"key":"bibr2-IMP3212","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2013.00293"},{"key":"bibr3-IMP3212","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.752376"},{"key":"bibr4-IMP3212","unstructured":"Influenza Antiviral Medications CDC. Summary for clinicians. (Accessed 10 August 2015.) Available from http:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/summary-clinicians.htm."},{"key":"bibr5-IMP3212","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-405880-4.00006-8"},{"key":"bibr6-IMP3212","unstructured":"Oseltamivir P.I. (2016). (Accessed 22 December 2016.) Available from https:\/\/www.gene.com\/download\/pdf\/tamiflu_prescribing.pdf."},{"key":"bibr7-IMP3212","doi-asserted-by":"publisher","DOI":"10.1086\/598513"},{"key":"bibr8-IMP3212","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12047"},{"key":"bibr9-IMP3212","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04623-14"},{"key":"bibr10-IMP3212","doi-asserted-by":"publisher","DOI":"10.1021\/jm5007275"},{"key":"bibr11-IMP3212","unstructured":"Kakuda T., Spittaels K., Vercauteren J. Single- and multiple-dose pharmacokinetics of JNJ-63623872 and interaction with oseltamivir in healthy volunteers.\n                      XVII International Symposium on Respiratory Viral Infections.\n                      Vancouver, BC, Canada, 6\u20138 March 2015. Abstract P7."},{"key":"bibr12-IMP3212","doi-asserted-by":"publisher","DOI":"10.1080\/0036554021000026960"},{"key":"bibr13-IMP3212","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00540.x"},{"key":"bibr14-IMP3212","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2011.00287.x"},{"key":"bibr15-IMP3212","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/135965359900400302","volume":"4","author":"Calfee D.P.","year":"1999","journal-title":"Antivir Ther"},{"key":"bibr16-IMP3212","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.13.1240"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:29Z","timestamp":1777380749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,1]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.3851\/IMP3212"],"URL":"https:\/\/doi.org\/10.3851\/imp3212","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,1]]}}}